felodipine has been researched along with Brain Vascular Disorders in 8 studies
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.
felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.
| Excerpt | Relevance | Reference |
|---|---|---|
| "All clinical studies of at least 1 week's duration with felodipine in patients with hypertension were included in a safety analysis." | 7.69 | Overview of the safety of felodipine based on clinical trials in patients with hypertension. ( Elmfeldt, D; Elvelin, L; Niklasson, A; Olsson, G; Welin, L, 1997) |
| " All patients were randomly assigned to take aspirin 75 mg/day or placebo, and patients in the aspirin group had a 15% lower rate of major cardiovascular events and myocardial infarctions than did patients who received placebo." | 6.19 | Aggressive blood pressure lowering is safe, but benefit is still hard to prove. ( Pohl, MA; Vidt, DG, 1999) |
| " the level of blood pressure associated with the lowest incidence of major cardiovascular events such as fatal and non-fatal stroke and myocardial infarction and other cardiovascular mortality); and (2) to assess the effect of a low dose of acetylsalicylic acid (aspirin) compared with placebo on major cardiovascular events." | 5.09 | The Hypertension Optimal Treatment study and the importance of lowering blood pressure. ( Hansson, L, 1999) |
| "In 102 patients with high risk (52 patients with history of myocardial infarction, 50 patients with history of cerebral stroke within previous 6-48 months) arterial hypertension (AH) we studied clinical efficacy on angiotensin converting enzyme inhibitor (ACEI) lisinopril, calcium antagonist felodipine, and nonselective - -blocker carvedilol in dependence on salt sensitivity of AH." | 3.76 | [Comparative eficacy of antihypertensive therapy in patients with arterial hypertension and various sensitivity to salt]. ( Babkin, AP; Gladkikh, VV; Gulaia, GI; Pershukov, IV, 2010) |
| " To study further the interactions between dietary salt intake and antihypertensive drug treatment, we examined the effects of felodipine, a dihydropyridine derivative Ca2+ channel antagonist with natriuretic properties, on blood pressure and the development of left ventricular hypertrophy in the stroke-prone spontaneously hypertensive rats during different levels of sodium chloride in the diet." | 3.69 | Cardiovascular effects of felodipine are not antagonized by dietary salt. ( Karppanen, H; Laakso, J; Mervaala, EM, 1994) |
| "All clinical studies of at least 1 week's duration with felodipine in patients with hypertension were included in a safety analysis." | 3.69 | Overview of the safety of felodipine based on clinical trials in patients with hypertension. ( Elmfeldt, D; Elvelin, L; Niklasson, A; Olsson, G; Welin, L, 1997) |
| "Because hypertension is a risk factor for stroke, and because severe BP elevation may increase oedema and the risk of haemorrhage, acute antihypertensive therapy might seem reasonable." | 1.29 | [Reducing hypertension may worsen symptoms of acute apoplexy]. ( Garde, E; Jørgensen, HS; Lassen, NA; Olsen, TS, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (87.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Babkin, AP | 1 |
| Gladkikh, VV | 1 |
| Pershukov, IV | 1 |
| Gulaia, GI | 1 |
| Garde, E | 1 |
| Jørgensen, HS | 1 |
| Olsen, TS | 1 |
| Lassen, NA | 1 |
| Mervaala, EM | 1 |
| Laakso, J | 1 |
| Karppanen, H | 1 |
| Welin, L | 1 |
| Elvelin, L | 1 |
| Niklasson, A | 1 |
| Olsson, G | 1 |
| Elmfeldt, D | 1 |
| Gueyffier, F | 1 |
| Boissel, JP | 1 |
| Parving, HH | 1 |
| Vidt, DG | 1 |
| Pohl, MA | 1 |
| Hansson, L | 1 |
1 review available for felodipine and Brain Vascular Disorders
| Article | Year |
|---|---|
Aggressive blood pressure lowering is safe, but benefit is still hard to prove.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
2 trials available for felodipine and Brain Vascular Disorders
| Article | Year |
|---|---|
Aggressive blood pressure lowering is safe, but benefit is still hard to prove.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
6 other studies available for felodipine and Brain Vascular Disorders
| Article | Year |
|---|---|
[Comparative eficacy of antihypertensive therapy in patients with arterial hypertension and various sensitivity to salt].
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carbazoles; Carvedil | 2010 |
[Reducing hypertension may worsen symptoms of acute apoplexy].
Topics: Acute Disease; Aged; Cerebrovascular Disorders; Diltiazem; Felodipine; Humans; Hypertension; Male; R | 1995 |
Cardiovascular effects of felodipine are not antagonized by dietary salt.
Topics: Animals; Blood Pressure; Cerebrovascular Disorders; Electrolytes; Felodipine; Heart Rate; Hemodynami | 1994 |
Overview of the safety of felodipine based on clinical trials in patients with hypertension.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Cerebrovascular Disorders; Double-Blind Method; F | 1997 |
Hypertension Optimal Treatment (HOT) trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel B | 1998 |
Hypertension Optimal Treatment (HOT) trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Blood Pressure; Calcium | 1998 |